font size
Sign in


The Rise in Drug Spending and
What It Means

Podcast: April 21, 2014

Reduced patent expirations, the introduction of the largest number of new drugs in a decade, and growing use of healthcare services helped increase total U.S. spending on drugs in 2013 by 3.2 percent, according to a new report from IMS Institute for Health Informatics. We spoke to the Institute’s Executive Director Murray Aitken about the report, what it tells us about the biopharmaceutical industry’s ability to bring innovative therapies to market, and the evolving debate of the cost and benefits of these new drugs.
Read More
Todays Stories
Podcast Personalizing Cancer Therapies with a Mouse

Joel Ackerman, CEO of Champions Oncology, discusses the personalization of cancer therapy, the benefits his company's mouse avatars provide, and how the same technology is being used to improve drug development.

By the numbers Biotech IPOs Cool Amid Market Jitters

Biotech IPOs have cooled considerably since the selloff of biotech stocks that began March 21. The two biotechs that went public on U.S. exchanges during the second week of April met with a muted reception by investors growing wary of a biotech bubble.